Made available in DSpace on 2015-07-22T20:50:00Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-10-27. Added 1 bitstream(s) on 2015-08-11T03:26:32Z : No. of bitstreams: 1 Publico-478a.pdf: 1748555 bytes, checksum: b181ae22edf209a657904d2ffd598714 (MD5). Added 1 bitstream(s) on 2015-08-11T03:26:32Z : No. of bitstreams: 2 Publico-478a.pdf: 1748555 bytes, checksum: b181ae22edf209a657904d2ffd598714 (MD5) Publico-478b.pdf: 1641358 bytes, checksum: 0e86ce5d9ab1f861e041d1c439ae3929 (MD5). Added 1 bitstream(s) on 2015-08-11T03:26:32Z : No. of bitstreams: 3 Publico-478a.pdf: 1748555 bytes, checksum: b181ae22edf209a657904d2ffd598714 (MD5) Publico-478b.pdf: 1641358 bytes, checksum: 0e86ce5d9ab1f861e041d1c439ae3929 (MD5) Publico-478c.pdf: 865894 bytes, checksum: 6c26a1bd60d04ccd988686846c01b9cf (MD5) / O presente estudo avaliou a eficácia e a tolerabilidade do topiramato nos pacientes com Transtorno de Estresse Pós-Traumático (TEPT). Foi realizado estudo clínico randomizado, duplo-cego e controlado comparando topiramato com placebo. Homens e mulheres entre 18 e 62 anos com diagnóstico de TEPT segundo os critérios do DSM-IV foram selecionados do ambulatório do Programa de Violência da Universidade Federal de São Paulo (Prove- UNIFESP) entre abril de 2006 e dezembro de 2009. Os participantes foram avaliados através da escala de TEPT administrada por clínicos (CAPS), escala de Impressão Clínica Global (CGI) e Inventário de Depressão de Beck (BDI). Após 1 semana de wash-out, trinta e cinco pacientes com TEPT foram randomizados para tratamento com topiramato ou placebo e acompanhados por 12 semanas. Foi observado que 82,35% dos pacientes que receberam topiramato apresentaram melhora dos sintomas do TEPT. Na análise de eficácia, os pacientes do grupo topiramato demonstrou demonstraram redução significativa dos sintomas de revivescência: memórias intrusivas, flashbacks e pesadelos (CAPS B; p=0,004) e sintomas de evitação e entorpecimento emocional (CAPS C; p = 0,0001). Além disso, encontramos melhora significativa do escore do CAPS total (topiramato –57,78; placebo –32,41; p = 0,0076) nos pacientes do grupo experimental. Topiramato foi bem tolerado e efetivo principalmente nos sintomas de revivescência e anestesia e evitação do TEPT. Este estudo dá suporte para o uso de anticonvulsivantes na melhora dos sintomas do TEPT. / The aim of this study was to evaluate the efficacy and tolerability of topiramate in patients with posttraumatic stress disorder (PTSD). We conducted a 12-week double-blind, randomized, placebo-controlled study comparing topiramate to placebo. Men and women aged 18 to 62 years with diagnosis of PTSD according to DSM-IV were recruited from the outpatient clinic of the violence program of Federal University of São Paulo Hospital (Prove- UNIFESP), São Paulo City, between April 2006 and December 2009. Subjects were assessed for the Clinician-Administered Posttraumatic Stress Scale (CAPS), Clinical Global Impression (CGI), and Beck Depression Inventory (BDI). After 1-week period of washout, 35 patients were randomized to either group. The primary outcome measure was the CAPS total score changes from baseline to the endpoint. In all 82.35% of patients in the topiramate group exhibited improvements in PTSD symptoms. The efficacy analysis demonstrated that patients in the topiramate group exhibited significant improvements in reexperiencing symptoms: flashbacks, intrusive memories, and nightmares of the trauma (CAPS-B; p = 0.04) and in avoidance/numbing symptoms associated with the trauma, social isolation, and emotional numbing (CAPS-C; p = 0.0001). Furthermore, the experimental group demonstrated a significant difference in decrease in CAPS total score (topiramate –57.78; placebo –32.41; p = 0.0076). Topiramate was generally well tolerated. Topiramate was effective in improving reexperiencing and avoidance/numbing symptom clusters in patients with PTSD. This study supports the use of anticonvulsants for the improvement of symptoms of PTSD. / TEDE / BV UNIFESP: Teses e dissertações